In 1993, we reviewed three fluoroquinolone antibiotics (ciprofloxacin, norfloxacin and ofloxacin).1 Since then, four more fluoroquinolones have been awarded marketing authorisations. Here we review the clinical evidence and discuss the place of two of these drugs, ▼grepafloxacin (Raxar - GlaxoWellcome) and ▼levofloxacin (Tavanic - Hoechst Marion Roussel). Sparfloxacin and trovafloxacin are not considered, as they are not yet commercially available.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.